A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Clinical trial NCT07207070 · RECRUITING
Trial details
- NCT number
- NCT07207070
- Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-12
- Primary completion
- 2029-05-31
- Enrollment
- 312
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.